Why the study?
Does the linear peptide antibody response to SARS-CoV-2 spike protein differ between vaccinated individuals and naturally infected individuals?
Does the linear peptide antibody response to SARS-CoV-2 spike protein differ between vaccinated individuals and naturally infected individuals?
Vaccinated individuals lack specific IgG binding to certain spike protein epitopes seen in naturally infected individuals, despite similar overall antibody binding activity.
Answers are grounded in this paper and cite their sources.
Epitope differences should not alter vaccination strategies; leaves open whether infection-specific responses confer distinct durability advantages.
Previous studies have attempted to characterize the antibody response of individuals to the SARS-CoV-2 virus on a linear peptide level by utilizing peptide microarrays. These studies have helped to identify epitopes that have potential to be used for diagnostic tests to identify infected individuals, however, the immunological responses of individuals who have received the currently available Moderna mRNA-1273 or Pfizer BNT162b2 mRNA vaccines have not been characterized. We aimed to identify linear peptides of the SARS-CoV-2 spike protein that elicited high IgG or IgA binding activity and to compare the immunoreactivity of infected individuals to those who received both doses of either vaccines by utilizing peptide microarrays. Our results revealed peptide epitopes of significant IgG binding among recently infected individuals. Some of these peptides are located near functional domains implicated in the high infectivity of SARS-CoV-2. Vaccinated individuals lacked these distinct markers despite overall binding activity being similar.
No takes yet. Share an insight, caveat, or question.
Albert Miller (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: